Background
==========

While advances have been made in breast cancer therapies, metastatic breast cancer remains an incurable disease, and thus the prevention of metastases must be a priority. The preference of breast cancer cells to grow in the bone and lung is underscored by the fact that 65-75% of patients with advanced disease develop metastasis in these organs \[[@B1]\]. We hypothesize that the pro-inflammatory microenvironment within the bone and lung caused by certain inflammatory conditions may partly account for the high prevalence of secondary metastasis to those organs.

One such common inflammatory condition in humans is autoimmune arthritis (AA) which results in inflammation and deformity of the joints. Other systemic effects associated with arthritis include increased cellular infiltration and inflammation of the lungs \[[@B2]\]. Although AA does not increase the risk for BC, several studies have reported that compared to cancer patients without rheumatoid arthritis (RA), those with RA have poor prognosis and higher mortality. Specifically, patients with non-Hodgkin\'s lymphoma, skin cancer, and BC have significantly lower survival if they suffer from RA compared to their non-arthritic counterparts \[[@B3]-[@B8]\].

Despite this knowledge available for a decade, it has not been fully studied in bones and lungs, the sites of chronic inflammation associated with AA, creates a milieu that attracts tumor cells to home and grow in the inflamed organs which are frequent sites of breast cancer metastasis \[[@B8]\]. There has been minimal research investigating the link between breast cancer-associated metastasis and arthritis even though both diseases share several common molecular pathways of pathogenesis and both diseases are highly prevalent in post menopausal women.

We have recently shown that the incidence of breast cancer-associated bone and lung metastasis was significantly higher in mice that develop spontaneous arthritis\[[@B9]\]. This was the first study that undoubtedly established a correlation between the pro-inflammatory microenvironment in bones and lungs during AA and the homing of circulating tumor cells in these sites of inflammation. Data from these studies were further substantiated in a clinically relevant model of spontaneous metastatic mammary carcinoma induced to develop arthritis. Hence, this study is a sequel of our previous study and our data corroborates a novel link between arthritis induced inflammation and secondary metastasis associated with breast cancer.

The model of spontaneous metastatic mammary gland tumors known as the MMTV-PyV MT mice carry the polyoma virus middle T-antigen driven by the mouse mammary-tumor virus promoter \[[@B10]-[@B12]\]. This oncogene is active throughout all stages of mammary gland development, resulting in widespread transformation and production of multifocal mammary adenocarcinomas with \~30-40% of the mice exhibiting lung metastasis by 18-26 weeks of age \[[@B10]-[@B13]\]. The PyV MT mice were induced to develop arthritis by administration of Type II Collagen (CII) at two time points: when the mice were 9 or 18 weeks of age designated pre-metastatic or metastatic stage respectively. The collagen-induced arthritis (CIA) model has been the most widely accepted model for inducing AA in mice. CIA is elicited in mice by immunization with CII emulsified in complete Freund\'s adjuvant (CFA). The ensuing pathogenesis shares several pathological features with rheumatoid arthritis (RA), including synovial hyperplasia, mononuclear cell infiltration, and cartilage degradation and the mechanism by which arthritis is induced by collagen injection in these mice is already established \[[@B14],[@B15]\].

Data clearly demonstrates a significant increase in bone and lung metastasis and decreased survival in the arthritic versus the non-arthritic PyV MT mice. In addition, we have identified some of the key proinflammatory factors in the arthritic lung and bone microenvironment and also in circulation that may contribute to the increased incidence of secondary metastasis. Further, we determined that blocking the COX-2/PGE~2~and IL-17 pathways significantly reduced the formation of secondary metastasis in the PyV MT mice.

This study is of high importance with vital clinical implications, especially in the prevention of metastasis, in designing combination drug regimens, and as a diagnostic risk-assessment tool in patients with arthritis and breast cancer.

Methods
=======

Mice
----

PyV MT oncogenic mice were originally a gift from Dr. W. J. Muller (McGill University, Toronto, Canada) \[[@B10]\]. The PyV MT mice that we have used are congenic on the C57Bl/6 background and have been used in several of our prior publications \[[@B13],[@B16]-[@B19]\]. PCR was used to routinely identify the PyV MT oncogene. PCR was carried out as described previously \[[@B13]\]. Amplification of PyV MT gene results in a 480-bp fragment.

All mice were bred and maintained in specific pathogen-free conditions in the Mayo Clinic Scottsdale Natalie Schafer Transgenic Animal Facility and UNCC Animal Facility. All experimental procedures were conducted according to Institutional Animal Care and Use Committee guidelines. All protocols were approved by the Mayo Clinic and UNCC Internal Animal Care Review Committee.

Induction of Arthritis
----------------------

The PyV MT mice with spontaneous breast cancer were injected with 50 μls of 2 mg/ml CII (MD Biosciences, St. Paul, MN, USA) in CFA (Difco laboratories, Michigan, USA) intradermally \~1.5 cms distal from base of tail at two time points, at 9 weeks of age when the primary tumors are undetectable and at 18 weeks of age when the primary tumors are large enough and metastasis is expected to occur \[[@B10],[@B11]\]. Fifty-sixty percent of mice develop arthritis within 15-30 days post collagen injection and the mechanism is established\[[@B14]\].

Generation of PyV MT cells
--------------------------

To generate the PyV MT cell line, the tumors were dissociated in collagenase IV (1 mg/ml)(Worthington Biochemical Corporation, 730 Vassar Ave, NJ 08701) at 37°C for 30 mins. Then the tumors were meshed, cells counted and \~3 × 10^6^cells were plated in C-DMEM. Post 24 hours cells were replenished with fresh media.

Measurement of PGE~2~levels in the serum
----------------------------------------

PGE~2~levels in the serum were determined as previously reported using a specific ELISA kit for PGE~2~metabolite (PGEM) (13, 14-dihydro-15-keto-PGA2) (Cayman Chemicals, Ann Arbor, MI, USA) \[[@B20]\]. Manufacturer\'s recommended protocols were followed. Serum was diluted appropriately to ensure that readings were within the limits of accurate detection. Results are expressed as picograms of PGEM/per ml. of serum.

Measurement of cytokines
------------------------

The RayBio^®^Custom Mouse Cytokines Antibody Array kit was purchased from Ray Biotech (Norcross, GA, USA) and used according to the manufacturer\'s instructions. To measure the cytokines in the lung and bone microenvironment, 300 and 100 ug of protein was used respectively. Chemiluminescence was detected using an EpiChemi3^®^Darkroom imaging system and Lab Works^®^densitometry software (both from UVP Bioimaging, Upland, CA, USA). Data was corrected for background signal and normalized to positive controls using RayBio^®^Analysis Tool software as published (UVP Bioimaging, Upland, CA, USA).

Invasion Assays
---------------

PyV MT cells were serum-starved for 24 hrs prior to plating for the invasion assay. Cells in serum free media (50,000 cells) were plated over transwell inserts (BD Biosciences, San Jose, CA), pre-coated with reduced growth factor matrigel, and were permitted to invade towards lung lysate (300 ug protein) and bone lysate (100 ug protein) contained in the bottom chamber for 24 hours. Percent invasion was calculated as absorbance of samples/absorbance of controls × 100 \[[@B21]\].

Histology
---------

Lungs and tumor sections were formalin fixed in 10% neutral-buffered formalin (pH 6.8-7.2) for a minimum of 24 hours. Paraffin embedded blocks was prepared by the Histology Core at The Mayo Clinic and 4-micron thick sections were cut for hematoxylin eosin (H&E) staining and for immuno-staining. Bones were decalcified using Cal-Rite (Richard Allan Scientific, Kalamazoo, MI), a formic acid decalcification agent prior to IHC. For VEGF, Pancytokeratin, and PCNA staining, sections were subjected to antigen retrieval using the DAKO Target Retrieval agent (Dako North America, Carpentaria, CA, USA). Primary antibodies to VEGF, PCNA, and pancytokeratin were purchased from Santa Cruz Biotechnologies, Santa Cruz, CA, USA and BD Biosciences, CA, USA). To determine macrophage infiltration, F4/80 antibody was purchased from Abcam, Cambridge, MA, USA. Corresponding secondary antibodies were purchased from DAKO. For all slides, 3,3\" -Diaminobenzidine (Vector laboratories, Burlington, CA, USA) was used as the chromogen and hematoxylin was used as counterstain. For neutrophil staining, a standard Naphthol AS-D Chloroacetate Esterase staining using a kit from Sigma was used. (Sigma, St Louis, MO, USA; Cat: \# 91C-1Kit) was used. Masson trichome staining on bone was used to determine levels of osteoclasts. All slides were examined under light microscopy and pictures taken at magnifications indicated in the Figure legend.

Western Blots and Antibodies
----------------------------

Equal quantities of tumor lysates were loaded on SDS-PAGE gels. COX-2 and β-actin antibodies were purchased from Santa Cruz Biotechnology, Santa Cruz, CA and were used according to manufacturer\'s recommendations.

Study design for the IL-17 + celecoxib treatment
------------------------------------------------

To test the efficacy of anti-IL-17 antibody treatment on breast cancer-associated metastasis, PyV MT mice were injected with 50 μls of 2 mg/ml CII in CFA at 12 wks. Post 3-weeks of collagen injection, four i.p injections of 5 μg/ml of anti-IL17 antibody (BD Pharmingen, San Diego, CA) once every two weeks was administered. Celecoxib (20 mg/kg in 100 μl 10% DMSO) was gavaged \[[@B22]\] starting at the same time as the anti-IL-17 antibody but was given daily until sacrifice except for the weekends. One week after the last injection, mice were sacrificed. Controls included PyV MT mice induced with arthritis and injected with 5 μg/ml rat immunoglobulin (Ig) G1 control antibody (BD Pharmingen, San Diego, CA) in 100 μl PBS.

Image Acquisition and Analysis
------------------------------

Bright field images were captured from immunostains of the mouse tissue using an Olympus microscope Olympus BX60, U-ND25-2 (Olympus; Melville, NY) with magnifications (referred in Figure Legend) using the DP70 controller, processor and analysis software.

Red-green-blue (RGB)-filtered grayscale values from images from microscopic slides of mouse tissue, stained with DAB, hematoxylin or both were analyzed using the Image-Pro Plus and NIH Image processing and analyzing program \[[@B22]\]. A simple translation algorithm using the RGB information was developed, providing the option for separation of DAB only- and double-stained areas from hematoxylin only-stained areas by means of subject specific thresholding, based on the correlations between the R-G- and B-filtered grayscale values. A good separation of DAB- and double-stained pixels from hematoxylin-stained pixels was achieved. Significant differences in relative areas stained and mean specific intensity for the stains between control and treatment groups in mouse tissue were tabulated. N = 3 mice and 5 fields are provided.

The densitometric analyses of immunoblots were performed using NIH Image (obtained from the NIH Web site: <http://rsb.info.nih.gov/nih-image>). Results are presented as mean values of arbitrary densitometric units corrected for background intensity and normalized to the expression of β-actin, or as fold increase over levels in unstimulated cells.

X-Ray imaging
-------------

The Pix array 100 x-ray machine was used for bone imaging. The Pix array 100 (Bi Optic Inc, Santa Clara, CA, USA) is a commercially available x-ray machine that is designed for animal x-ray\[[@B23]\]. The analysis was conducted in Carolinas Medical Center within the Department of Orthopedic Surgery.

Statistical analysis
--------------------

Data were analyzed using GraphPad software (GraphPad Prism version 4.00 for Windows; GraphPad Software, San Diego, CA, <http://www.graphpad.com>). Results expressed as mean ± SEM and are representative of greater than or equal to three separate experiments. Comparison of groups were performed using one-way or two-way ANOVA followed by the Bonferroni post-test for multiple comparisons (\*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001). Student\'s t-test was used for comparing the level of significance between the experimental groups.

Results
=======

Decreased survival in arthritic versus non-arthritic PyV MT mice
----------------------------------------------------------------

Survival was assessed in PyV MT mice that were induced to develop autoimmune arthritis (AA) with collagen II injection at week 9 week of age. The PyV MT mice develop hyperplasia when the mice hit puberty around 6-8 weeks of age followed by carcinoma-in-situ and palpable mammary gland tumors by 12-14 weeks of age leading to invasive adenocarcinoma by 18-24 week of age. Thus, we were able to study the effect of arthritis on survival when AA was induced at the pre- metastatic stages (at 9 weeks of age). This model is clinically relevant, as tumors arise in an appropriate microenvironment, in the context of a viable immune system, and are phenotypcially similar to human breast tumors. The survival of the PyV MT mice was significantly diminished with collagen-induced arthritis where all arthritic mice had to be euthanized by 149 days (\~ 21 weeks) due to high tumor burden, ulceration of tumor, sluggish motion, hunched back and interferences with normal ambulation compared to 170+days (\~24-25 weeks) for PyV MT mice without arthritis (P \< 0.001)(Figure [1A](#F1){ref-type="fig"}).

![**Lower survival coupled with higher tumor burden of the arthritic versus non-arthritic PyV MT mice**. **A:**Significant diminution in the survival of arthritic versus non-arthritic PyV MT mice. N = 6 mice \[\*p \< 0.01 (CII injected at 9 wks of age)\]. **B:**Significantly higher tumor burden in arthritic versus non- arthritic PyV MT mice. N = 10 mice. \*p \< 0.01 (CII injected at 9 or 18 weeks) compared to non-arthritic PyV MT mice.](1471-2407-11-365-1){#F1}

Remodeling of the primary mammary gland tumor in arthritic PyV MT mice
----------------------------------------------------------------------

PyV MT mice were induced to develop autoimmune arthritis with collagen II injections at week 9 and week 18 of age (pre and post metastatic stage). We questioned if the primary tumor itself was affected by the arthritic milieu. The primary tumor burden was significantly increased in the PyV MT mice with arthritis compared to PyV MT mice without arthritis (P \< 0.01, n = 10-13 mice) (Figure [1B](#F1){ref-type="fig"}) regardless of whether arthritis was induced at pre or post-metastatic stage. Higher tumor burden correlated with increased cellular infiltration within the tumor microenvironment which was determined by quantifying the areas of infiltration in the H&E stained tumor sections (Figure [2A-F](#F2){ref-type="fig"}).

![**Increased cellular infiltration within the PyV MT tumors of arthritic versus non-arthritic mice**. **A - F:**H&E staining showing inflammation in the tumor microenvironment; **A and D:**PyV MT (Low inflammation); **B and E**: PyV MT + CII at 9 (severe inflammation); C and F: PyV MT + CII at 18 wks (severe inflammation). The images of tumor sections were taken at 200× (**A-C**) and 400× (**D-F**) magnification from the same area. Representative of n = 10 mice is shown. **G-L**: Increased macrophage infiltration within the PyV MT tumors of arthritic versus non-arthritic mice indicated by F4/80 staining. The images of the macrophage staining were taken at 600× magnification. Representative of n = 3 mice is shown.](1471-2407-11-365-2){#F2}

Integrated density was used to quantify the levels of infiltrating cells. Quantification was based on 5 fields with n = 3 tumor sections per experimental group and presented in Table [1](#T1){ref-type="table"}. Further, we show increased macrophage infiltration within the PyV MT tumors of arthritic versus non-arthritic mice indicated by F4/80 staining (Figure [2G-L](#F2){ref-type="fig"}). The number of F4/80 positive cells have been counted in 5 fields in n = 3 tumor sections from each experimental group and results documented in Table [2](#T2){ref-type="table"}. This was accompanied by increased levels of proliferating cell nuclear antigen (PCNA) staining (Figure [3A-C](#F3){ref-type="fig"}) within the tumor implying higher proliferation in the arthritic versus the non-arthritic tumors. Table [3](#T3){ref-type="table"} shows the number of PCNA-positive cells in 5 sections in n = 3 tumors from each experimental group. Since cyclooxygenase-2 (COX-2) and vascular endothelial growth factor (VEGF) are hallmarks of inflammation, angiogenesis, and metastasis, we investigated the expression of COX-2 and VEGF in the tumors of our experimental mice. Western blotting was used to determine COX-2 levels and IHC used to determine VEGF levels. Significant increases in VEGF and COX-2 expression was detected in the primary tumors of the arthritic versus the non-arthritis PyV MT mice (Figure [3D-F](#F3){ref-type="fig"} and Figure [3G](#F3){ref-type="fig"}). IHC and Western blots were quantified and results reported in Tables [4](#T4){ref-type="table"} and [5](#T5){ref-type="table"}. Data suggests that the induction of AA in PyV MT mice creates a pro-inflammatory and angiogenic microenvironment in the primary tumor, further promoting tumor progression. All IHC staining were quantified using the Image-Pro Plus and NIH Image processing and analysis programs.

###### 

Quantification of inflammation in the tumors of arthritic versus non-arthritic PyV MT mice.

  Quantification in tumor   IntDen Inflammation
  ------------------------- ---------------------
  PyV MT                    50.3 ± 19
  PyV MT + CII at 9 wks     322 ± 17
  PyV MT + CII at 18 wks    337 ± 22

Integrated density (IntDen) from 5 fields per tumor in n = 3 animals from each experimental group.

###### 

F4/80 positive cells in the tumors of arthritic versus non-arthritic mice (5 fields from n = 3 mice were counted).

  -------------------------------------------------------------------------------------------------------------------------------
                             F4/80\                                                                                  
                             positive cells\                                                                         
                             at 600×\                                                                                
                             magnification                                                                           
  -------------------------- ----------------- ------------- ------------- ------------- ------------- ------------- ------------
                             **Field 1**       **Field 2**   **Field 3**   **Field 4**   **Field 5**   **Average**   **StdDev**

                                                                                                                     

  PyV MT 1                   1                 1             2             0             0             0.8           0.84

                                                                                                                     

  PyV MT 2                   0                 0             4             1             1             1.2           1.64

                                                                                                                     

  PyV MT 3                   3                 1             2             0             0             1.2           1.30

                                                                                                                     

  PyV MT + CII at 9 wks 1    23                15            12            4             5             11.8          7.79

                                                                                                                     

  PyV MT + CII at 9 wks 2    19                7             10            18            17            14.2          5.36

                                                                                                                     

  PyV MT + CII at 9 wks 3    22                16            18            21            16            18.6          2.79

                                                                                                                     

  PyV MT + CII at 18 wks 1   23                15            19            14            16            17.4          3.65

                                                                                                                     

  PyV MT + CII at 18 wks 2   18                18            12            13            22            16.6          4.10

                                                                                                                     

  PyV MT + CII at 18 wks 3   17                23            15            19            17            18.2          3.03
  -------------------------------------------------------------------------------------------------------------------------------

![**Increased expression of PCNA, VEGF and COX-2 in the arthritic PyV MT tumors**. **A-C**: Higher number of PCNA positive cells in the tumors of arthritic PyV MT versus non-arthritic PyV MT. **D-F:**Increased expression of VEGF in the arthritic PyV MT tumors. The images of tumors were taken at 200× magnification. Brown staining represents positive PCNA and VEGF staining. Representative of n = 10 mice is shown. **G:**Western blot analysis of COX-2 expression. β-actin serves as control for equal protein loading.](1471-2407-11-365-3){#F3}

###### 

PCNA positive cells in the tumors of arthritic versus non-arthritic mice (5 fields from n = 3 mice were counted).

                             PCNA positive cells at 400× magnification                                                                         
  -------------------------- ------------------------------------------- ------------- ------------- ------------- ------------- ------------- ------------
                             **Field 1**                                 **Field 2**   **Field 3**   **Field 4**   **Field 5**   **Average**   **StdDev**
                                                                                                                                               
  PyV MT 1                   50                                          30            34            50            55            43.8          11.05
                                                                                                                                               
  PyV MT 2                   27                                          40            50            25            32            34.8          10.28
                                                                                                                                               
  PyV MT 3                   34                                          37            48            53            50            44.4          8.38
                                                                                                                                               
  PyV MT + CII at 9 wks 1    100                                         87            92            95            84            91.6          6.35
                                                                                                                                               
  PyV MT + CII at 9 wks 2    105                                         94            86            96            107           97.6          8.56
                                                                                                                                               
  PyV MT + CII at 9 wks 3    97                                          80            78            94            73            84.4          10.50
                                                                                                                                               
  PyV MT + CII at 18 wks 1   120                                         80            125           115           85            105           20.92
                                                                                                                                               
  PyV MT + CII at 18 wks 2   97                                          112           87            88            94            95.6          10.06
                                                                                                                                               
  PyV MT + CII at 18 wks 3   89                                          75            96            74            85            83.8          9.36

###### 

Quantification of VEGF staining in tumors (Average IntDen from 5 fields per tumor from n = 3 mice is shown).

  Quantification in tumor   IntDen
  ------------------------- -------------
                            **VEGF**
                            
  PyV MT                    424.93 ± 19
                            
  PyV MT + CII at 9 wks     2021.8 ± 21
                            
  PyV MT + CII at 18 wks    2788.8 ± 28

###### 

Densitometry analysis of the COX-2 expression in the tumor using the image J software **(**data from n = 3 mice is shown)

  Groups                     Densitometry analysis: COX2
  -------------------------- -----------------------------
  PyV MT 1                   22.28
                             
  PyV MT 2                   24.21
                             
  PyV MT 3                   21.67
                             
  PyV MT + CII at 9 wks 1    41.65
                             
  PyV MT + CII at 9 wks 2    40.45
                             
  PyV MT + CII at 9 wks 3    50.23
                             
  PyV MT + CII at 18 wks 1   58.17
                             
  PyV MT + CII at 18 wks 2   55.41
                             
  PyV MT + CII at 18 wks 3   45.15

Significant increase in osteolytic metastatic lesions in the arthritic PyV MT versus non-arthritic PyV MT mice
--------------------------------------------------------------------------------------------------------------

We observed that 50% of arthritic PyV MT mice developed bone metastasis while none of the non-arthritic PyV MT mice showed bone metastasis (Figure [4](#F4){ref-type="fig"}). Bones from n = 8 mice were analyzed by x-ray imaging for osteolytic lesions. Representative images from these groups are shown in Figure [5A-F](#F5){ref-type="fig"}. Clear osteolytic lesions were evident in the femur of the arthritic but not the non-arthritic PyV MT bones (as indicated by the arrow). The control C57BL/6 mice induced with arthritis did not show any lesions which confirms that the osteolytic lesions are driven by the primary mammary gland tumors.

![**Percentage of mice with bone metastasis**. Fifty percent of arthritic PyV MT mice developed bone metastasis compared to its non-arthritic counterpart with no bone metastasis (n = 10-13 mice).](1471-2407-11-365-4){#F4}

![**Metastatic bone lesions accompanied with increased expression of Pancytokeratin in the bones of arthritic PyV MT mice**. **A-F:**Representative x-ray images of bones. **A-D:**Bones from C57/BL6 mice injected with CII at 9 and 18 wks and PyV MT mice with no metastatic lesions; **E and F**: Bones from PyV MT + CII at 9 wks and 18 wks respectively (shows distinct severe osteolytic bone lesion in distal femur as indicated by the arrow). N = 8 mice from each group were examined using the x-ray imaging. **G-I:**Pancytokeratin positive staining observed in the bones of arthritic PyV MT mice. Brown staining represents positive staining. The images were taken at 400× magnification. Representative of n = 10 mice is shown.](1471-2407-11-365-5){#F5}

To further confirm epithelial cell lesions, the bone sections were stained with pancytokeratin and results are shown in Figure [5G-I](#F5){ref-type="fig"}. Clear lesions are detected in the arthritic PyV MT bones but not in the non-arthritic PyV MT bones.

Significant increase in lung metastasis in the arthritic PyV MT mice
--------------------------------------------------------------------

We observed \>2-fold increase in the incidence of lung metastasis in the arthritic versus non-arthritic PyV MT mice (7/10 mice with CII administered at 18 wks, and 9/13 mice with CII injected at 9 wks) compared to the PyV MT mice with no CII (3/11 mice) (Figure [6](#F6){ref-type="fig"}). Lung lesions were visualized under dissecting microscope as indicated by arrows (Figure [7A-F](#F7){ref-type="fig"}) and by H&E staining and histology showing clear metastasis (indicated by arrows) (Figure [7G-L](#F7){ref-type="fig"}). These results are especially significant since it represents true metastasis arising from the spontaneously occurring primary mammary gland tumors.

![**Percentage of PyV MT mice that developed lung metastasis**. PyV MT mice + CII at 9 and 18 wks had two fold increase in lung metastasis as compared to PyV MT without CII (n = 10-13 mice).](1471-2407-11-365-6){#F6}

![**Images demonstrating clear metastatic lesions in the lungs of arthritic PyV MT mice**. **A-F:**Representative images of lungs showing metastatic lesions. **A-C:**C57/BL6 mice, C57/BL6+CII at 9 and 18 wks (no metastatic lesions) **D**: PyV MT mice(no metastatic lesions); **E and F:**PyV MT+ CII at 9 and 18 wks respectively (arrows represent lung lesions); **G-L:**H&E of the lung sections: The arrows represent metastatic lesions in PyV MT + CII at 9 and 18 wks (K and L) versus no lesions in control C57/BL6, C57/BL6 + CII at 9 or 18 wks and PyV MT lung (G - J). N = 10-13 mice from each group were examined with similar results. The images of the H&E sections were taken at 400× magnification.](1471-2407-11-365-7){#F7}

Significant inflammation detected in the bones and lungs of arthritic PyV MT mice
---------------------------------------------------------------------------------

To decipher why primary tumor cells are attracted to the arthritic bones, we initially conducted histology of bone sections from all six experimental groups. Representative images of H&E staining are shown in Figure [8A-F](#F8){ref-type="fig"} for bone sections from C57/BL6, C57BL/6 + CII at 9 wks, C57BL/6 + CII at 18 wks, PyV MT, PyV MT + CII at 9 wks, and PyV MT + CII at 18 wks. Enhanced inflammation with increased cellular infiltration was clearly observed in the C57/BL6 bones from arthritic mice as compared to the non-arthritic C57BL/6 and PyV MT bones. The severity of inflammation was augmented with arthritic PyV MT bones suggesting that the metastatic PyV MT tumor may have the potential to enhance the severity of arthritis (Figure [8A-F](#F8){ref-type="fig"}). N = 8 mice were evaluated with similar results. The results are tabulated as integrated density (IntDen) from n = 3 mice in Table [6](#T6){ref-type="table"}. Inflammatory signals are known to induce osteoclast maturation and bone resorption during CII-induced arthritis. Such phenomena mainly occur at the interface between proliferating synovium and bone tissue in arthritis. High cellular infiltration in the arthritic PyV MT mice was associated with increased bone destruction as evidenced by the increased osteoclasts in these mice (Figure [8G-L](#F8){ref-type="fig"}) as compared with PyV MT with no CII. Taken together these data suggest that the metastatic breast cancer cells may contribute to the vicious cycle of osteolytic destruction.

![**Histology of bones and lungs, and osteoclast staining of bones of the arthritic versus non-arthritic PyV MT mice**. **A-F:**H&E staining of sections from the joints. **A:**C57BL/6 (no inflammation)**; B:**C57BL/6 mice + CII at 9 wks (moderate inflammation); **C:**C57BL/6 mice + CII at 18 wks (moderate inflammation); **D:**control PyV MT mice (no inflammation); **E:**PyV MT mice + CII at 9 wks (erosion of articular cartilage and bone with severe inflammation); **F**: PyV MT mice + CII at 18 wks (severe inflammation in the phalangeal joints); **G-L:**Masson trichome staining of bone sections for presence of osteoclasts. **G:**C57/BL6 mice (no osteoclasts); **H:**C57BL/6 + CII at 9 wks (few osteoclasts marked with arrows); **I:**C57BL/6 mice + CII at 18 wks (few osteoclasts marked with arrows); **J:**PyV MT mice (no osteoclasts); **K**: PyV MT mice + CII at 9 wks (multiple osteoclasts marked with arrows); **L:**PyV MT mice + CII at 18 wks (multiple osteoclasts marked with arrows). **M-R:**H&E staining of sections from the lungs. **M:**control C57BL/6 (no inflammation); **N:**C57BL/6+CII at 9 wks(moderate inflammation); **O:**C57BL/6+CII at 18 wks(moderate inflammation); **P**: control PyV MT mice (no inflammation); **Q:**PyV MT mice + CII at 9 wks (severe inflammation); **R:**PyV MT mice + CII at 18 wks (severe inflammation). The H&E images of the joints and lungs were taken at 200× and 400× magnification respectively and the Masson Trichome bone images taken at 400× magnification. Representative of n = 10 mice is shown.](1471-2407-11-365-8){#F8}

###### 

Quantification of inflammation in the bones (Average IntDen from 5 fields per bone from n = 3 mice is shown).

  Quantification of inflammation in bone   
  ---------------------------------------- ------------
  **Group**                                **IntDen**
                                           
  C57BL/6                                  0
                                           
  C57BL/6 + CII at 9 wks                   50 ± 38
                                           
  C57BL/6 + CII at 18 wks                  72 ± 12
                                           
  PyVMT                                    0.0
                                           
  PyV MT +CII at 9 wks                     232 ± 15
                                           
  PyV MT +CII at 18 wks                    265 ± 20

To further demonstrate the chemotactic microenvironment in the lungs of arthritic versus non-arthritic mice, lung histology was examined. Moderate inflammation was noted in the C57BL/6 mice with arthritis compared to no inflammation in the non-arthritic C57BL/6 lungs. Significantly enhanced inflammation with increased cellular infiltration was observed in the lungs of PyV MT mice injected with collagen compared to PyV MT mice without collagen and compared to control C57BL/6 mice with collagen (Figure [8M-R](#F8){ref-type="fig"}). The pro-inflammatory phenotype in the lung correlated with the severity and incidence of lung metastasis (Figure [7](#F7){ref-type="fig"}) suggesting the critical role of inflammatory cells in promoting metastasis.

In addition, we demonstrate neutrophillic infiltration in the bones and lungs of arthritic versus non-arthritic PyV MT mice, another indicator of increased inflammation in the arthritic organs. Representative images are shown in Figure [9A-C](#F9){ref-type="fig"} for bones and Figure [9D-F](#F9){ref-type="fig"} for lungs from the arthritic and non-arthritic PyV MT mice.

![**Increased infiltration of neutrophils in the bones and lungs of arthritic PyV MT mice**. **A-F:**Naphthol AS-D chloroacetate esterase staining of the bones and lungs for neutrophils. Increased infiltration of neutrophils in **bones (A-C) and lungs (D-F)**of arthritic PyV MT mice indicated by arrows. Representative of 10 fields in n = 10 mice is shown. The images of the bones and lungs were taken at 400× and 200× magnification respectively.](1471-2407-11-365-9){#F9}

Enhanced invasion of PyV MT tumor cells towards arthritic bone and lung lysate
------------------------------------------------------------------------------

Thus far, our data suggests that the increased cellular infiltration in the lungs and bones of the arthritic mice versus the non-arthritic mice may be one of the underlying mechanisms for the increased rate of metastasis observe in the arthritic mice (Figures [4](#F4){ref-type="fig"}, [5](#F5){ref-type="fig"}, [6](#F6){ref-type="fig"}, [7](#F7){ref-type="fig"}, [8](#F8){ref-type="fig"}, [9](#F9){ref-type="fig"}). To substantiate the chemotactic potential of the arthritic bone and lung, bone and lung lysates of the arthritic and non-arthritic mice were used as the chemotactic factor in an *in vitro*trans-well matrigel invasion assay with the PyV MT cells (generated from primary PyV MT tumors) in the top chamber and the bone and lung lysates in the bottom chamber. Data clearly shows that the lung and bone microenvironment was significantly altered in the arthritic mice to become more chemo-attractant to the PyV MT tumor cells (Figure [10A](#F10){ref-type="fig"} and [10B](#F10){ref-type="fig"}). Statistically significant difference is provided between PyV MT and PyV MT + CII at 9 and 18 weeks as well as C57Bl/6 and C57Bl/6 + CII at 9 and 18 weeks.

![**Higher invasion of PyV MT cells towards the bone and lung lysate of the arthritic versus non-arthritic PyV MT mice**. Up regulation of several cytokines in the lung and tumor microenvironment. **A and B:**Significantly higher invasion index of the PyV MT tumor cells towards the arthritic bone and lung lysate in an *in vitro*matrigel invasion assay (\* p \< 0.05 compared to the non-arthritic PyV MT lung and bone lysate). **C and D:**A graphical representation of the up regulated cytokines in the bone and lung lysate (\*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001). The Ray Biotech cytokine array kit was utilized for this experiment. Average of n = 4 mice. The statistical differences between groups are shown with horizontal bars. We have compared 1) C57Bl/6 with C57Bl/6 + CII at 9 and 18 weeks; and 2) PyV MT with PyV MT + CII at 9 and 18 weeks.](1471-2407-11-365-10){#F10}

IL-17, IL-6, Pro-MMP9, IGF-II, and M-CSF may be the underlying factors responsible for the increased metastasis in the lungs and bones of arthritic mice
--------------------------------------------------------------------------------------------------------------------------------------------------------

To determine which factors in the bone and lung microenvironment may be responsible for higher invasion, thereby driving the breast cancer cells to become more metastatic in the arthritic model, we used the RayBio^®^Custom Mouse Cytokines Antibody Array. The arthritic lungs and bones expressed significantly higher levels of cytokines and growth factors which included IL-17, IL-6, Pro-MMP9, IGF-II, and M-CSF (Figure [10C](#F10){ref-type="fig"} and [10D](#F10){ref-type="fig"}). This was regardless of whether the arthritis was induced at 9 or 18 wks of age suggesting that the arthritic milieu remains stable even at 10-12 weeks post CII injection. The levels of the pro-inflammatory cytokines were found to be higher in arthritic C57BL/6 lungs and bones compared to the non-arthritic C57BL/6.

Thus, we hypothesize that the pro-inflammatory microenvironment in the arthritic bone and lungs may boost the recruitment of the PyV MT tumor and that the PyV MT tumor in turn significantly augments the levels of the cytokines in these target organs thus creating a highly conducive microenvironment for the PyV MT tumors to further proliferate.

High levels of circulating PGE~2~coupled with increased levels of pro-inflammatory cytokines in circulation may initiate primary tumors to be more metastatic in arthritic milieu
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

We also evaluated the circulating levels of pro-inflammatory cytokines and chemokines in the sera of the arthritic versus the non-arthritic mice. These same factors (IL-17, IL-6, Pro-MMP9, IGF-II, and M-CSF) were also found to be elevated in the circulation suggesting their role in possibly initiating the primary tumors to be more metastatic (Figure [11A](#F11){ref-type="fig"}). Data is presented as densitometry units.

![**Serum analysis revealed up regulation of various cytokines along with PGE2 which may be the underlying factor contributing to increased metastasis in arthritic mice**. **A:**A graphical representation of the up regulated cytokines in the bone and lung lysate (\*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001). The Ray Biotech cytokine array kit was utilized for this experiment and average of n = 4 mice. **B:**Increased circulating PGE~2~in the arthritic versus the non-arthritic PyV MT mice (\*p \< 0.01 versus PyV MT mice), n = 10 mice per group. A specific ELISA was used for this experiment. The statistical differences between groups are shown with horizontal bars. We have compared the statistical differences between 1) C57Bl/6 with C57Bl/6 + CII at 9 and 18 weeks; and 2) PyV MT with PyV MT + CII at 9 and 18 weeks.](1471-2407-11-365-11){#F11}

Lastly, but expectedly, we detected significant increase in PGE~2~levels in the circulation (Figure [11B](#F11){ref-type="fig"}). Elevated PGE~2~is a hall mark of arthritis and is known to enhance primary tumor cells to become highly angiogenic and metastatic.

Treatment with anti-IL-17 and a COX-2 inhibitor significantly reduced the secondary metastasis in the arthritic PyV MT mice
---------------------------------------------------------------------------------------------------------------------------

The goal of our studies is to find a possible therapy for arthritis-induced breast cancer metastases. Both IL-17 and COX-2 are reasonable targets as both were up-regulated in the arthritic mice and both are used clinically for treatment of arthritis. IL-17 is known to also mediate proinflammatory effects by stimulating the release of multiple other cytokines such as IL-6, IL-8, GM-CSF, TGF-β, TNF-α and G-CSFs from epithelial, endothelial, and fibroblastic cells. In addition, it is an emerging therapeutic target for cancer metastasis and arthritis \[[@B24]-[@B26]\]. High levels of cyclooxygenase 2 (COX-2) is linked to both AA and breast cancer metastasis \[[@B27]\]. We treated the arthritic PyV MT mice with a combination of celecoxib, a specific COX-2/PGE~2~inhibitor, and a neutralizing antibody against IL-17. Excitingly, the incidence of secondary metastasis was significantly reduced in the arthritic PyV MT mice treated with a combination of celecoxib and a neutralizing antibody against IL-17 (Figure [12A](#F12){ref-type="fig"} and [12B](#F12){ref-type="fig"}). Lysates from metastatic sites in treated mice were further evaluated for their chemo attractant properties and were found to be significantly less attractant than bone and lung lysates from untreated arthritic PyV MT mice (Figure [12C](#F12){ref-type="fig"} and [12D](#F12){ref-type="fig"}). In fact the level of chemo attractant was as low as the non-arthritic PyV MT mice suggesting that the anti-IL-17 antibody and celecoxib reduced the levels of IL-17 and PGE~2~which in turn reduced the levels of all other factors that were up regulated in the arthritic lung and bone lysates (data not shown).

![**Treatment with anti-IL17 antibody and celecoxib significantly reduced secondary metastasis in the arthritic PyV MT mice**.Percent of mice that developed **A)**bone and **B)**lung metastasis post treatment. Fifty percent decrease in bone and lung metastasis in mice treated with the combination therapy. N = 4 mice per group. **C and D:**Percent of PyV MT cells that invaded through the matrigel in an *in vitro*invasion assay with **C)**bone lysate or **D)**lung lysate in the bottom chamber. Lysates from lung and bone of treated arthritic PyV MT mice were significantly less chemotactic than lysates from untreated arthritic PyV MT mice. (\* p \< 0.05). N = 3 from each group. The statistical differences between groups are shown with horizontal bars. The statistical differences were compared between 1) C57Bl/6 with C57Bl/6 + CII at 9 and 18 weeks; and 2) PyV MT with PyV MT + CII at 9 and 18 weeks.](1471-2407-11-365-12){#F12}

Discussion
==========

Inflammation is a critical component of tumor progression and metastasis as well as arthritis \[[@B28]-[@B31]\]. Many processes that occur during arthritis also occur during tumorigenesis including uncontrollable growth, inflammation, increased vascularity and common cytokines and growth factors that are regulated in both. The tumor microenvironment, which is largely orchestrated by inflammatory cells, is critical in the neoplastic process, fostering proliferation, survival and migration \[[@B32]\]. It is indeed interesting that post-menopausal women who are usually prone to developing some form of autoimmune arthritis including osteoarthritis, RA, or inflammatory polyarthritis are also the most likely candidates to develop breast cancer. Thus, it is not unlikely that the two diseases co-exist in these women. Although there are several studies implicating inflammation as the initiator of tumor formation and/or mediator of progression, there is minimal research on whether prior inflammation at the site of metastasis produces a fertile ground for primary tumor cells to home and proliferate. Our study begins to evaluate whether arthritis which causes inflammation in the bones and lungs enhances secondary metastasis to those sites. A significant increase in breast cancer-associated metastasis to the lungs and bones was observed in the arthritic versus the non-arthritic PyV MT mice (Figures [4](#F4){ref-type="fig"}, [5](#F5){ref-type="fig"}, [6](#F6){ref-type="fig"}, [7](#F7){ref-type="fig"}) along with increase in primary tumor burden (Figure [1](#F1){ref-type="fig"}). Compared with the non-arthritic C57BL/6, the lungs and bones of the arthritic C57BL/6 expresses moderate levels of inflammation even before any tumor challenge suggesting a pro-inflammatory milieu that may be responsible for attracting the PyV MT metastatic cells to the lungs and bones as demonstrated in the *in vitro*invasion assay (Figure [10A](#F10){ref-type="fig"} and [10B](#F10){ref-type="fig"}). Once the PyV MT cells home to the lungs or bones, the levels of interstitial cellular infiltrates and pro-inflammatory cytokines are exponentially increased which is characterized by prominent cytokines IL-17, IL-6, Pro-MMP9, IGF-II and M-CSF (Figure [10C](#F10){ref-type="fig"} and [10D](#F10){ref-type="fig"}). The levels of these cytokines along with PGE~2~are also upregulated in the circulation (Figure [11A](#F11){ref-type="fig"} and [11B](#F11){ref-type="fig"}). These pro-inflammatory cytokines along with inflammatory microenvironment can facilitate tumor cell extravasation and promote metastasis. This is further substantiated when treatment with celecoxib + αIL-17 antibody significantly reduced the metastasis to lung and bone (Figure [12](#F12){ref-type="fig"}). This study undoubtedly authenticates our previous study \[[@B9]\].

The tumor microenvironment itself is regarded as a \"smoldering\" inflammation site in which many cytokines, chemokines, and enzymes mediate the inflammatory process and drive malignant progression \[[@B33]\]. We observed increased inflammation into the tumor site of the arthritic PyV MT mice possibly remodeling the tumor microenvironment (Figure [2](#F2){ref-type="fig"}). For tumors to develop in size and amplify metastatic potential, they must make an \"angiogenic switch\" through perturbing the local balance of pro-angiogenic and anti-angiogenic factors. Frequently, tumors over express pro-angiogenic factors, such as PGE~2~and VEGF, allowing them to make this angiogenic switch \[[@B34]\]. We observed increased VEGF and COX-2 expression in the tumors of arthritic PyV MT mice compared to non-arthritic tumors (Figure [3](#F3){ref-type="fig"}) possibly inducing an \"angiogenic switch\" and contributing to invasiveness of the cells.

Cytokines and prostaglandins play an essential role in the development of arthritis \[[@B35]\]. Several cytokines have been implicated in the mechanism of synovial cell activation and joint destruction in AA \[[@B36]\]. At the same time, cytokines also play an imperative role in cancer development and progression. In fact, elevated serum M-CSF predicts reduced survival in metastatic breast cancer patients \[[@B37]\]. At the same time, the M-CSF produced by breast cancer cells and surrounding stroma increases osteoclast formation and maturation and enhances the expression of stromal RANK ligand, both of which increase osteolytic bone degradation \[[@B38]\]. M-CSF also contributes to the pathogenesis of RA through up regulation of neutrophil gelatinase-associated lipocalin (NGAL) in neutrophils, followed by induction of transitional endoplasmic reticulum ATPase (TERA), cathepsin D and transglutaminase 2(TG2) in synoviocytes \[[@B39]\]. Pro-MMP9 concentration in sera and joint fluids of RA patients is reported to be significantly higher which correlates with our mouse model where the Pro-MMP9 levels are up regulated in the arthritic bone, lungs microenvironment as well as in the sera \[[@B40]\]. It is reported that cathepsin G is up regulated through tumor stromal interactions and activates Pro-MMP9, active MMP9 cleaves and releases active TGF-beta, and active TGF-beta can then promote tumor growth and enhance osteoclast activation and subsequent bone resorption \[[@B41]\]. Over expression of IGF-II is reported in multiple types of cancer and is proposed as a potential mechanism for cancer cells to develop resistance to IGF-1R-targeting therapy \[[@B42]\]. IL-17 acts on osteoblasts by stimulating COX-2-dependent PGE~2~and osteoclast differentiation factor which differentiates osteoclast progenitors into mature osteoclasts, causing bone resorption. PGE~2~interacts with its eicosanoid receptors to induce the damage \[[@B26]\]. It is found that synovial fluids of patients with RA contain high levels of the cytokines IL-17 and IL-15 \[[@B43]\]. Cytokines play a crucial role in the regulation of inflammatory events. Inflammatory disorders such as RA are characterized by an overproduction of several cytokines including IL-6 \[[@B44]\]. IL-6 on the other hand is an autocrine and paracrine growth factor for several cancers, including breast cancer \[[@B45],[@B46]\] and both IL-17 and IL-6 stimulates cancer cell growth and contributes to recurrence and metastasis in breast cancer \[[@B47]-[@B49]\].

Conclusion
==========

The data clearly shows that breast cancer associated metastasis is increased in arthritic conditions and blocking the IL-17 and COX-2 pathways significantly reduces the development of secondary metastasis in a spontaneous model of breast cancer induced to develop arthritis.
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